Anti-OX40, Cyclophosphamide (CTX) and Radiation in Patients With Progressive Metastatic Prostate Cancer
Status:
Completed
Trial end date:
2016-07-05
Target enrollment:
Participant gender:
Summary
This clinical trial will examine a novel combination of anti-OX40 to induce proliferation of
memory and effector T cells in conjunction with cyclophosphamide (CTX) and radiation to
induce tumor antigen release with the overall goal of promoting an immune response against
prostate cancer.